(100CAP020-2) In vivo Resistant Mechanisms of Sorafenib in Hepatocellular Carcinoma (HCC)---Development of Predictive Biomarkers and Resistance-Reversing Strategies (II)

2012-05-012024-05-13https://scholars.lib.ntu.edu.tw/handle/123456789/646820(100CAP020-2) In vivo Resistant Mechanisms of Sorafenib in Hepatocellular Carcinoma (HCC)---Development of Predictive Biomarkers and Resistance-Reversing Strategies (II)